SEP 27 2026
Elevar Therapeutics — lirafugratinib
for cholangiocarcinoma
Accepted MAR 30 2026.
About
Cholangiocarcinoma is a cancer that forms in the bile ducts and can cause abdominal pain, severe itching, and jaundice. Lirafugratinib is a drug designed to target and block the activity of the FGFR2 protein in tumors. This approach could potentially slow the growth of bile duct cancers driven by specific FGFR2 genetic changes.
Pivotal trial
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor
Source: ClinicalTrials.gov
Drug Watch — recent news on lirafugratinib
- HLB to Present Rivoceranib and Lirafugratinib Research at European Oncology Congress - 아시아경제
- HLB says FDA review of bile duct cancer drug lirafugratinib enters final stage - koreabiomed.com
- HLB’s FDA Late-Cycle Meeting for Lirafugratinib Concludes Without Major Issues - 아시아경제
- HLB's Liver Cancer Drug Hit with Third CRL; Lirafugratinib Emerges as Key Catalyst Ahead of September FDA Decision - finance.biggo.com
- Elevar Begins Global Phase 2 Lirafugratinib Trial - Businesskorea